Scientific Compendium

Category: Scientific Compendium

LifeViz Scientific Compendium:
54 Published Studies on 3D Clinical Imaging

Measured outcomes, not impressions.

The LifeViz® Scientific Compendium gathers 54 peer-reviewed publications and conference proceedings (2011–2026) in which independent investigators used 3D stereophotogrammetry to measure clinical results objectively: volume, surface, wrinkle depth, roughness, scar size, lesion size or wound area. Many of these studies used LifeViz® 3D imaging.

Download the Scientific Compendium (PDF)

54 studies · 3 clinical fields · 31 journals and proceedings
NEW

The compendium at a glance

Item Detail
Studies54
Publication span2011–2026
Journals and proceedings31
Clinical fieldsAesthetics (35 studies), Dermatology (14), Wounds (5)
What is measuredVolume, surface, wrinkle depth, skin roughness, scar volume, lesion size, wound area
Imaging solutions referencedLifeViz Mini (3D facial), LifeViz Micro (skin micro-topography), LifeViz Infinity (3D body), DermaViz / LifeViz 2D (skin analysis)

What is 3D stereophotogrammetry in clinical imaging?

3D stereophotogrammetry reconstructs the shape of the face, body or skin surface from images captured at the same moment from different angles. Because every scan is standardized and calibrated, the same area can be measured before and after treatment, in millimetres or millilitres, and compared over time. It replaces subjective assessment (scales, visual impressions) with reproducible, measured data.

What the studies show

  • Reliability and validation. Published validation work reports intraclass correlation of 0.732–0.976 for facial measurements between and within examiners (Ceinos et al., 2016), 55 µm accuracy and 8 µm precision with a 0.999 correlation between injected and measured volumes on phantoms (Skvara et al., 2012), ICC 0.98 repeatability for atrophic acne scar volume (Petit et al., 2018), and concordance of 0.989 with transparent tracing for venous leg ulcer area (Chaby et al., 2017).
  • Objective measurement versus human raters. In a laser study of wrinkles and scars, 3D imaging correctly detected no change in untreated controls, while human raters overestimated improvement (Machado et al., Scientific Reports, 2021).
  • Durability of dermal fillers. In a 6-month multicenter trial, 67.7% of the week-3 cheek volume correction was still maintained at month 6 on 3D analysis (Kestemont et al., 2012). In an observational study of 39 patients, mid-face volume restoration was 4.46 mL at 45 days and 1.23 mL remained at 318 days (Diaspro & Sito, 2025).
  • Botulinum toxin and soft-tissue repositioning. 3D analysis measured a 24% reduction of static glabellar lines at 90 days (Rappl et al., 2018) and documented volume change and soft-tissue displacement after toxin-based lifting techniques (case reports and prospective studies).
  • Body contouring and cellulite. 3D body imaging was used to quantify abdominal volume loss, and, for diluted calcium hydroxylapatite on the buttocks, a 50.09% reduction in dimple depth and 54% fewer visible dimples at 14 weeks in 24 participants (Durairaj et al., 2024).
  • Scars. In a randomized controlled trial, laser-treated post-operative scars showed better volume (p = 0.004), surface (p = 0.017) and roughness (p = 0.002) at 1 year (Casanova et al., 2017).
  • Dermatology and oncology. 3D imaging was used to track lesion volume and surface in basal cell carcinoma, HPV-induced lesions and neurofibromas, and to quantify tumor shrinkage after photodynamic therapy (Bullock et al., 2020).

 

These are findings reported by the original authors. Several studies evaluate third-party treatments; their inclusion does not imply endorsement of those products.

Browse the compendium by clinical field

Aesthetics (35 studies, 2012–2026)

Dermal fillers (cheeks, midface, lips, temples, nose and chin), botulinum toxin, thread lifting, lasers and scars, cellulite and body contouring, skin boosters, energy devices, skincare.

Study (first author, year) Journal Topic Key reported result
Kestemont, 2012Journal of Drugs in DermatologyHA filler, cheeks (6 months)67.7% of week-3 volume maintained at month 6 on 3D analysis
Ceinos, 2016Journal of Esthetic and Restorative DentistryReliability of facial and dental measurementsICC 0.732–0.976 for facial measurements
Casanova, 2017Aesthetic Plastic Surgery1210-nm laser, post-operative scars (RCT, 1 year)Better volume, surface and roughness vs control at 1 year
Kerscher, 2017Clinical, Cosmetic and Investigational DermatologyTwo HA fillers, midface, split-face (18 months)CPM-26 non-inferior to VYC-20 at month 3; greater volume at every time point
Rappl, 2018Aesthetic Plastic SurgeryBotulinum toxin A, glabellar lines (90 days)−24% static glabellar lines at day 90
Moradi, 2020Journal of Cosmetic DermatologyTopical body treatment after cryolipolysis or radiofrequencyGreater abdominal volume loss vs placebo, p = 0.0078 at week 12
Machado, 2020Aesthetic Plastic SurgeryLaser-assisted delivery, periorbital wrinklesVitamin C + growth factors superior to vitamin C alone (p < 0.01)
Machado, 2021Scientific Reports3D vs IGAIS clinical scale, wrinkles and scars3D correlated with the scale; no false gains in untreated controls
Machado, 2021Aesthetic Plastic SurgeryLaser-assisted delivery, scarsBoth groups improved; growth factors added benefit (p < 0.01)
Wong, 2021Journal of Clinical & Experimental Dermatology ResearchPrejuvenation, pigmentation (2 patients)Measurable decrease in pigment count
Torres, 2021Kosmetische MedizinHA filler, cheekbones, curved cannula (300 days)Results better than baseline up to day 300
Diaspro, 2021Dermatologic TherapyThread lifting, midface (350 days)+5.59 mL at 120 days; +4.16 mL at 350 days
Chernoff, 2021Journal of Clinical and Cosmetic DermatologySea salt exfoliation, ultrasound and LEDNo adverse reactions reported
Tanzi, 2021PMID 34224601Acoustic subcision, cellulite (multicenter pivotal trial)−29.5% mean cellulite reduction (56 participants)
Carruthers, 2021Aesthetic Surgery JournalTopical body treatment vs bland moisturizerVolar forearm roughness p = 0.004; most other differences not significant
Rogério, 2022Brazilian Dental ScienceFull-face botulinum toxin, tissue repositioning (case report)+1.59 mL left and +1.17 mL right cheekbone
Wu, 2023Plastic and Reconstructive Surgery – Global OpenIncobotulinumtoxinA, glabellar lines (phase 3)92.5% vs 95.1% responders; non-inferiority confirmed
Chernoff, 2023Journal of Cosmetic DermatologyExosomes and calcium hydroxylapatite (40 patients)16 of 20 infusion patients very satisfied, 4 satisfied
Germani, 2023Journal of Cosmetic DermatologyInfraorbital hollows, "Toxin Lift"0.54 mm cranial skin displacement at 15 days
Fanian, 2023Journal of Dermatological TreatmentHA micro-filler, superficial wrinkles (146 randomized)Wrinkle reduction vs control at day 75 and day 120
Salti, 2023Dermatologic SurgeryXTRCL filler, midface (6 months)Significant improvement in volume and skin quality
Durairaj, 2024Aesthetic Plastic SurgeryDiluted CaHA, buttock cellulite (24 participants)−50.09% dimple depth; 54% fewer visible dimples at 14 weeks
Germani, 2024Aesthetic Surgery Journal Open ForumTwo HA fillers for lips (RCT)Lip volume increase at 30 days with the OBT gel, P = .014
Rogerio, 2024Journal of Oral Biology and Craniofacial ResearchDeoxycholic acid by microcannula (case report)−14.81 mL submental volume after two sessions
Vitale, 2024International Journal of Clinical Studies and Medical Case Reports675-nm laser, mixed melasma (case series)Improved pigmentary and vascular components
Siquier-Dameto, 2024Dermatologic SurgeryDEFCL filler, midface (12 months)Volume and skin quality maintained at 12 months
Kim, 2024Plastic and Reconstructive Surgery – Global OpenHA filler, temple hollowness (25 women)3D volume 0.86 mL at 3 months and 0.72 mL at 6 months
Ramirez, 2024n/aSuperficial ultrasound and diluted CaHA (pilot, 12 subjects)Skin roughness improved significantly at week 24 (all P < 0.001)
Diaspro & Sito, 2025Surgeries (MDPI)HA gel, mid-face (318 days, 39 patients)4.46 mL at 45 days; 1.23 mL still measured at 318 days
Nomoto, 2025Journal of Cosmetic DermatologyLongevity serum, split-face (5 subjects)Trend toward improved radiance, firmness and laxity; small sample
Salti, 2025Journal of Cutaneous and Aesthetic SurgeryDEFCL filler, midface (18 months, 50 women)94% global aesthetic improvement at month 18
Yonsei University (Kim et al.), 2026International Journal of Molecular SciencesParticulated human ADM skin booster (split-face and preclinical)Greater skin-volume gain than HA control over 20 weeks
Son, 2026Aesthetic Surgery Journal Open ForumHA filler YYS 720, nose and chin (18 months)Chin volume 1.73 mL at month 18 (P = .0061)
Erlich, 2026Lasers in Medical ScienceXERF dual-frequency radiofrequency (16 women)Improved laxity and skin quality at 3 months (preliminary)
Espinosa, 2026CureusJawline botulinum toxin, neck effect (case report)Neck volume −6.92 mL and −2.41 mL (two sides) at 15 days

Dermatology (14 studies, 2011–2024)

3D lesion quantification and validation (basal cell carcinoma, HPV lesions, acne scars), plus clinical trials and imaging studies in psoriasis, onychomycosis, atopic dermatitis, skin hydration and AI-based acne grading.

Study (first author, year) Journal Topic Key reported result
Skvara, 2011Journal of Investigative DermatologyTopical smoothened inhibitor, basal cell carcinoma in NBCCS (8 patients)Most basal cell carcinomas responded vs vehicle
Skvara, 2012Skin Research and Technology3D stereovision camera validation55 µm accuracy, 8 µm precision, 0.999 correlation between injected and measured volumes
Sofen, 2015Journal of the American Academy of DermatologyVismodegib in operable basal cell carcinoma (phase II)Complete histologic clearance 42%, 16% and 44% by cohort; primary endpoints not met
Hogendoorn, 2015Clinical Therapeutics (conference abstract)3D photography, skin lesion quantification (phantom)Coefficient of variation ≤ 2.6% across operators, skin backgrounds and days
Gottlieb, 2017Journal of the American Academy of DermatologySecukinumab, palmoplantar psoriasis (GESTURE)33.3% clear or almost clear (300 mg) vs 1.5% placebo at week 16
Petit, 2018Skin Research and Technology3D imaging, atrophic acne scars (31 patients)ICC 0.98 repeatability; r = 0.77 with global severity ratings
Reich, 2019British Journal of DermatologySecukinumab, nail psoriasis (TRANSFIGURE)NAPSI −63.2% at week 32 (300 mg)
Gottlieb, 2019British Journal of DermatologySecukinumab, palmoplantar psoriasis, 2.5 years59.2% clear or almost clear at 2.5 years (300 mg)
Rijsbergen, 2019Journal of the European Academy of Dermatology and Venereology3D photography, HPV-induced skin lesionsICC ≥ 0.86 between raters; reproducibility CVs ≤ 2%
Bullock, 2020Proceedings of SPIEVitamin D and photodynamic therapy, basal cell carcinoma80% final clinical clearance of 45 lesions after three treatments
Gupta, 2021Journal of the American Academy of DermatologyTopical terbinafine 10%, onychomycosis (phase 3)69.9% mycological cure vs 27.7% vehicle at week 52
Cork, 2023Conference abstractDupilumab, skin barrier in children aged 6–11Non-lesional skin reached TEWL levels comparable to healthy skin at week 16
Nguyen, 2024Journal of Drugs in DermatologyFacial hydration heatmaps (pilot)Hydration shifted from about 12–42 AU to 30–60 AU at 30 minutes
Bernhard, 2024n/aDeep learning, acne severity grading66.67% test accuracy on a small, imbalanced dataset

Wounds (5 studies, 2017–2020)

Wound area measurement, cutaneous lesion volume, and preclinical and protocol work in wound healing.

Study (first author, year) Journal Topic Key reported result
Chaby, 2017n/a3D imaging vs transparent tracing, venous leg ulcers (36 patients)CCC 0.989 for ulcer area; 0.996 for the 4-week healing rate
Slopis, 2018Drugs in R&DEverolimus, cutaneous lesions in neurofibromatosis-1 (phase II)Significant surface volume reduction in 13% of lesions; p = 0.048 for average height
Wagner, 2018Preclinical study (mouse model)Irradiated PBMC secretome, wound closureFaster closure with the complete secretome in diabetic mice
Holbert, 2019TrialsHydrogel dressing, pediatric burns (study protocol)Protocol only, no results reported
Karner, 2020Scientific ReportsFecal-bacteria wound infection model (mouse)Significantly delayed wound healing (p < 0.05)

Frequently asked questions

What is the LifeViz Scientific Compendium?

A collection of 54 published studies (2011–2026) in which clinicians and researchers used 3D stereophotogrammetry to quantify clinical outcomes in aesthetics, dermatology and wound care. Many of them used LifeViz® 3D imaging.

The studies are published by independent investigators in 31 journals and conference proceedings, including Dermatologic Surgery, Aesthetic Plastic Surgery, Journal of the American Academy of Dermatology, Scientific Reports and the British Journal of Dermatology. Quartier Latin compiles and summarizes them; the findings are those of the original authors.

Aesthetics (35 studies), dermatology (14) and wounds (5).

Facial and body volume (in mL), soft-tissue displacement, wrinkle depth, skin roughness, scar volume and surface, lesion size and volume, and wound area.um dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Validation studies in the compendium report high reproducibility, for example ICC 0.732–0.976 for facial measurements (Ceinos 2016), ICC 0.98 for acne scar volume (Petit 2018) and CCC 0.989 against transparent tracing for ulcer area (Chaby 2017). See the full publications for methods and limitations.

LifeViz Mini (3D facial imaging), LifeViz Micro (skin micro-topography), LifeViz Infinity (3D body imaging) and DermaViz / LifeViz 2D (2D skin analysis). Older publications use previous names: QuantifiCare, 3D LifeViz Mini, LifeViz Micro or DermaPix. Quartier Latin S.A.S. is the former aesthetics division of QuantifiCare.

Always refer to the full original publication. Each summary in the PDF links to the source (DOI or PMID).

Check the full publication first, including its methods and limitations, before citing any result in a clinical or commercial context.

Important information

These summaries are provided for scientific information only. They report the methods, findings and conclusions of the original authors and are not claims made by Quartier Latin. Several studies evaluate third-party treatments; their inclusion does not imply endorsement of those products. Please refer to the full publications for complete methods, results and limitations.

 

Last updated: November 2026 (Edition October 2026) · © 2026 Quartier Latin S.A.S. · LifeViz® is a registered trademark.